Penumbra Secures CE Mark in Europe for Lightning Flash 2.0 and Lightning Bolt 7 Thrombectomy Technologies
Portfolio Pulse from Benzinga Newsdesk
Penumbra, Inc. has secured CE Mark in Europe for its latest thrombectomy technologies, Lightning Flash 2.0 and Lightning Bolt 7, enhancing its position in the vascular treatment market.
September 16, 2024 | 7:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Penumbra has received CE Mark approval in Europe for its new thrombectomy technologies, Lightning Flash 2.0 and Lightning Bolt 7, which are expected to improve vascular treatment outcomes.
The CE Mark approval allows Penumbra to market its new thrombectomy technologies in Europe, potentially increasing its market share and revenue. The technologies are expected to improve treatment outcomes, which could lead to higher adoption rates and positive investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100